Rare diseases
Investigational molecules
Locations
47 Little France Crescent, Bioquarter, EH16 4TJ, United Kingdom
Research activity includes osteogenesis imperfecta, with interest in therapies aimed at reducing fracture risk and supporting skeletal strength. The focus extends to treatment strategies involving parathyroid hormone analogues and bisphosphonates, as well as sequential approaches to bone protection.
These interests reflect a clinical emphasis on inherited skeletal disease and interventions that target bone density and structural resilience.
University Of Edinburgh runs clinical trials in conditions such as Cerebral haemorrhage, Osteogenesis imperfecta, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Belgium
DenmarkIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
